<DOC>
	<DOC>NCT03055611</DOC>
	<brief_summary>Elocta (rFVIIIFc) and Alprolix (rFIXFc) are recombinant extended half-life coagulation factor products. The purpose of this non-interventional study is to describe the real-world usage and effectiveness of Elocta and Alprolix in the prophylactic treatment of haemophilia A and B.</brief_summary>
	<brief_title>A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Have a diagnosis of haemophilia A or B and previously treated with factor Product Have started prophylactic Elocta/Alprolix treatment within 3 months prior to enrollment visit, or at enrollment prescribed prophylactic treatment with Elocta or Alprolix regardless of participation in the study Signed and dated informed consent provided by the patient, or the patient's legally acceptable representative for patients under the legal age, Before any studyrelated activities are undertaken. Assent should be obtained from paediatric patients according to local regulations. Enrollment in concurrent Clinical interventional study involving intake of an investigational Product (IMP), within Three months prior to enrollment visit.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Blood Coagulation Disorder</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Coagulation Protein Disorder</keyword>
	<keyword>Hemorrhagic Disorder</keyword>
	<keyword>Genetic Diseases, Inborn</keyword>
</DOC>